ABCB5抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using ABCB5 mouse mAb against A431 (1) cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of HepG2 cells using ABCB5 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.    

  
  

•  

   

     Flow cytometric analysis of HepG2 cells using ABCB5 mouse mAb (green) and negative control (purple).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human liver cancer tissues using ABCB5 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human breast cancer tissues using ABCB5 mouse mAb with DAB staining.    

  
  

ABCB5. a member of the ATP-binding cassette (ABC) transporter family, is a transmembrane protein initially identified for its role in chemoresistance by effluxing therapeutic agents. It is expressed in normal tissues like skin, ocular epithelium, and gastrointestinal tract, where it regulates cell differentiation and stem cell maintenance. However, ABCB5 gained prominence as a biomarker for tumor-initiating cells (TICs) in cancers, particularly melanoma. Studies show ABCB5+ cancer cells drive tumor progression, metastasis, and therapy resistance due to enhanced drug extrusion and stem-like properties.

ABCB5-specific antibodies, developed to target extracellular epitopes, have become critical tools for research and diagnostics. These monoclonal antibodies enable precise detection of ABCB5 expression via flow cytometry, immunohistochemistry, or immunofluorescence, aiding in cancer cell isolation and characterization. Clinically, ABCB5 expression correlates with poor prognosis in melanoma, colorectal cancer, and glioblastoma, making it a potential biomarker for patient stratification.

Therapeutically, anti-ABCB5 antibodies are explored to inhibit ABCB5-mediated chemoresistance or directly target cancer stem cells. Preclinical models demonstrate that blocking ABCB5 enhances chemotherapy efficacy. Additionally, antibody-drug conjugates (ADCs) or bispecific antibodies leveraging ABCB5’s surface expression are under investigation. Notably, ABCB5’s immunomodulatory role in regulatory T cells (Tregs) suggests potential synergy with immune checkpoint inhibitors. Early-phase trials for ABCB5-targeted therapies, particularly in refractory melanoma, highlight its translational relevance. Overall, ABCB5 antibodies bridge mechanistic insights into cancer stemness with emerging diagnostic and therapeutic applications. (298 words)